Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.
about
Lactate dehydrogenase A in cancer: a promising target for diagnosis and therapyRelationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancerComprehensive fluorogenic derivatization-liquid chromatography/tandem mass spectrometry proteomic analysis of colorectal cancer cell to identify biomarker candidate.Bevacizumab plus chemotherapy as third- or later-line therapy in patients with heavily treated metastatic colorectal cancer.A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growthPrognostic and predictive role of lactate dehydrogenase 5 expression in colorectal cancer patients treated with PTK787/ZK 222584 (vatalanib) antiangiogenic therapy.Correlation of NRAS mutations with clinical response to high-dose IL-2 in patients with advanced melanomaGenome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal CancerPre-treatment lactate dehydrogenase levels as predictor of efficacy of first-line bevacizumab-based therapy in metastatic colorectal cancer patientsPrognostic clinical factors in pretreated colorectal cancer patients receiving regorafenib: implications for clinical management.The correlation between LDH serum levels and clinical outcome in advanced biliary tract cancer patients treated with first line chemotherapy.Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II studyHigh-Throughput Screening to Identify Plant Derived Human LDH-A Inhibitors.Multi-biomarker pattern for tumor identification and prognosis.Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.Basal and bevacizumab-based therapy-induced changes of lactate dehydrogenases and fibrinogen levels and clinical outcome of previously untreated metastatic colorectal cancer patients: a multicentric retrospective analysis.Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.An immunohistochemical study of the expression of the hypoxia markers Glut-1 and Ca-IX in canine sarcomas.Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer.Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab.Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.
P2860
Q26851585-BEA119BD-4F62-4BD4-B95E-C8167043292EQ28068654-75A8003B-DB3D-4D6B-8F1F-FDC071109A4BQ31092607-7749A7A2-4DC6-44C0-AB32-13E000FA808FQ33425820-0A36DFD1-D139-439D-92AB-33E24A03E321Q34718277-68E5366B-E72E-48D9-B242-AEB2B810EFCBQ35132401-C655D56B-D779-4546-802F-7500C3E44858Q35621653-632614A2-5E77-4B48-94FA-46FA5CC658A6Q35722688-35CBCFDA-6B70-4233-ACA7-9B61DFEE874BQ35835193-6DE5F2B1-26D0-4D43-A7E5-46B7093E74F4Q36545358-FB2801BE-8716-488C-9AA3-E676BBAC1129Q36785251-172C1662-2534-41BC-8B65-6E11C6EA9905Q37121673-8CB7D8EB-06AB-4E2C-BC19-DF4A435B0A55Q37519163-B4B93B2C-0AF4-484F-90C6-87C0C44FC9E6Q37890322-17339777-B231-4C3B-9FE7-7E234751D794Q38312076-36302AB9-3B5B-478E-BDA4-B07237BD0A6CQ42468728-31C5818F-9951-46BA-A286-B889D40F409DQ45236702-B4E45A27-3C08-46C6-8FA1-2EF2C76AC7DCQ46187727-98B4BD62-CC91-4101-81C1-A4AD2CA666B8Q51031708-FED88D95-D35F-4B6A-8A56-2039FB3B711DQ51195465-AE03CC70-7472-45F7-9C9B-4E93FE8BF7C5Q54630883-4E06A045-79E7-4B09-8AB8-C06C21C9E6ABQ55421771-5B27320E-B1A0-4BCA-AFB0-D3D24051E000
P2860
Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.
description
2007 nî lūn-bûn
@nan
2007 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@ast
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@en
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@nl
type
label
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@ast
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@en
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@nl
prefLabel
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@ast
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@en
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@nl
P2093
P2860
P1433
P1476
Serum lactate dehydrogenase le ...... on in metastatic CRC patients.
@en
P2093
Andrew Sherod
Anthony El-Khoueiry
Carl Barrett
Christian J Jacques
Humphrey Gardner
Kathleen D Danenberg
Michael Shi
Mizutomo Azuma
Peter V Danenberg
Syma Iqbal
P2860
P304
P356
10.2217/14622416.8.12.1705
P577
2007-12-01T00:00:00Z